CARB-X Complete Portfolio, as of 6/30/25

Since CARB-X was launched in July 2016

CARB-X GRADUATES - THERAPEUTICS

Product Developer & Graduation Date	Product	Bacteria	Novelty*			Development Stage			
			New Abx Cls	New Abx Tgt	Non trad	Hit-to-lead	Lead Optimization	Pre-Clinical	Phase 1
Peptilogics 12/24	PLG0206: Direct-acting engineered peptides	Broad spectrum	•		•				
Trellis Bioscience 5/24	TRL1068: Antibiofilm monoclonal antibody	Broad spectrum	•	•	•				
Clarametyx Biosciences 11/22	CMTX-101: Antibiofilm Monoclonal Antibody	ESKAPE, MRSA	•	•	•				
GlaxoSmithKline 12/21	GSK3882347: FimH Antagonist UTI	*E. coli*	•	•	•				
Entasis Tx. 12/20	ETX0282CPDP: Oral Combination	Gram-negative pathogens							
Tetraphase 06/19	TP-6076: Novel Fluorocycline	*Acinetobacter, Enterobacteriaceae*							
Iterum 03/19	Sulopenem	Gram-negative activity							
Spero 03/18	SPR741: Antibiotic Potentiator	Gram-negative activity	•		•				
Oppilotech 10/17	LPS	Gram-negative pathogens							

CARB-X GRADUATES - PREVENTATIVES

Product Developer & Graduation Date	Product	Bacteria	Novelty*	Development Stage			
			Type	Hit-to-lead	Lead Optimization	Pre-Clinical	Phase 1
GlaxoSmithKline 06/25	GSK iNTS-TCV iNTS-typhoid conjugate vaccine	*Salmonella enterica*	Vaccine				
Seres 04/21	SER-155: LBP Cocktail Preventative	Broad spectrum activity vs CRE/VRE	Microbiome				
Vedanta 09/18	VE303: LBP Cocktail Preventative	*C.difficile*	Microbiome				

CARB-X GRADUATES - DIAGNOSTICS

Product Developer & Graduation Date	Product	Syndrome	Healthcare Level	Development Stage			
				Feasibility	Optimization	Develop-ment	Verification & Validation
Pattern Bioscience 06/23	Digital culture single cell biometric analysis	Lower respiratory tract infections	LIV				
Helixbind 03/22	Rapid/BSI, Automated culture-free	Bloodstream infections	LIV				
Proteus 02/22	Rapid POC Dx, Optical bacterial imaging	Lower respiratory tract infections	LIV				
Specific Diagnostics 03/20	SPECIFAST REVEAL™, Colorimetric Sensor Array to detect VOCs	Bloodstream infections	LIV				
T2 Biosystems 09/19	Expanded bacteria and resistance panels for T2Dx	Bloodstream infections	LIV				

*Note: Regarding CARB-X graduates, red bars represent Development Stage while in the CARB-X porfolio, and pink bars represent Development Stage progress after graduating from the CARB-X program.

Active Product Pipeline, as of 6/30/25

Products currently funded and supported by CARB-X

ACTIVE - THERAPEUTICS PROJECTS

Product Developer	Product	Bacteria	Novelty*			Development Stage			
			New Abx Cls	New Abx Tgt	Non trad	Hit-to-lead	Lead Optimization	Pre-Clinical	Phase I
ArrePath	Novel target antibiotic to treat UTIs caused by MDR Entobacterales	Gram-negative pathogens		•					
Justus Liebig University Giessen	Peptide antbiotic designed to inhibit BamA protein	Gram-negative pathogens	•	•					
Bugworks Research	GYROX: Gyrase-topoisomerase inhibitor	Gram-negative pathogens	•						
Macro Biologics (formerly Amicrobe)	Amicidin-β: Local antimicrobial	Broad spectrum	•		•				
Tamrisa	EBL-1463: Non -beta-lactam PBP inhibitor	CRE bacteria	•						
Debiopharm	Debio1453: FabI inhibitor	*Neisseria gonorrhoeae*	•						
Cellics Therapeutics	Macrophage Nanosponge: sepsis inhibitor	Broad spectrum toxins & cytokines	•	•	•				
Centauri Therapeutics	ABX01 program: Dual acting large molecule	Gram-negative pathogens	•	•	•				
Basilea (formerly Spexis/Polyphor)	LptA-OMPTA: LPS transport inhibitor	*Enterobacteriaceae* CRE	•	•	•				
GangaGen Biotech	Klebicins: Engineered proteins	*Klebsiella pneumoniae*	•	•	•				
Helmholtz Centre HZI	HZI-LDC: *S. aureus* α -hemolysin Inhibitors	*Staphylococcus aureus*	•	•	•				
The University of Melbourne at the Doherty Institute	PBT2: Antibiotic potentiator	CABP bacteria	•	•	•				
Locus Biosciences	LBP-KP01: CRIPSR-Cas3 Bacteriophages	*Klebsiella pneumoniae*	•	•	•				
Harvard University - Myers Lab	Oxepanoprolinamides: oral translation inhibitor	CABP/SSTI bacteria	•						

ACTIVE - PREVENTATIVES PROJECTS

Product Developer	Product	Bacteria	Type	Hit-to-lead	Lead		

Product Developer	Product	Bacteria	Type	Hit-to-lead	Optimization	Pre-Clinical	Phase I
Immunethep	Vaccine to prevent *E. coli*	*E. coli*	Vaccine				
Immunartes	Monoclonal anitbody	*Staphylococcus aureus*	Vaccine				
Clarametyx	Antibiofilm vaccine	*Klebsiella pnuemoniae*	Vaccine				
Peptilogics	zaloganan-CR: Engineered peptide to treat fracture-related infections	Broad spectrum	XR Peptide				
University of Maryland	Maternal vaccine that prevents sepsis	*Klebsiella pnuemoniae*	Vaccine				
LimmaTech	Multivalent Gonococcus vaccine	*N. gonorrhoeae*	Vaccine				
Syntiron	Alloy-EK vaccine	*E. coli* and *K. pneumoniae*	Vaccine				
Intravacc	Outer Membrane Vesicle vaccine	*N. gonorrhoeae*	Vaccine				
SNIPR BIOME ApS	SNIPR001 CRISPR-engineered preventative	*E. coli*	Bacteriophage				
LimmaTech	LBT-SA7 (formerly IBT-V02) Multi-valent vaccine	*S. aureus*	Vaccine				
GlaxoSmithKline	GSK Strep A vaccine	Group A Streptococcus	Vaccine				
Vedanta	VE707 Microbiome	CRE - ESBLs	Microbiome				
Vaxdyn	KAPAVAX Trivalent vaccine	Gram-negative pathogens	Vaccine				
Lumen Bioscience	LMN-GI-EEC-401 Oral antimicrobial immunotherapy (mAb)	*C. jejuni* & enterotoxigenic *E. coli*	Biologic				

ACTIVE - DIAGNOSTICS PROJECTS

Product Developer	Product / Technology	Syndrome	Healthcare Level	Feasibility	Optimization	Develop-ment	Verification & Validation
Pearl	Urine assay to detect pneumonia caused by *Pseudomonas aeruginosa*	Bacterial Pnuemonia	LI				
AstraDx	Rapid diagnostic to detect neonatal sepsis	Blood Stream Infections	LI				
Rhode Island Hospital	PCR test informed by RNA sequencing to detect bacterial pneumonia from whole blood	Blood Stream Infections	LI				
Melio	Rapid diagnostic to detect neonatal sepsis	Blood Stream Infections	LI				
Scout	Point-of-care test to detect and differentiate *N. Gonorrhea* and *C. trachomatis*	Sexually transmitted infections	LI				
Prompt	Portable PCR platform to detect multiple pathogenic bacteria targets and AST	Sexually transmitted infections	LI				
Fuse	Rapid, instrument-free diagnostic for the detection of *C. Trachomatis* and *N. Gonorrhoeae*	Sexually transmitted infections	LI				
Avails Medical	Rapid Electronic AST	Bloodstream infections	LIII/LIV				
Visby Medical	Rapid detection of *N. Gonorrhea* and antimicrobial susceptibility from urogenital samples	Sexually transmitted infections	LI				
Day Zero Diagnostics	ID & AST Whole genome sequencing & machine learning	Bloodstream infections	LIV				
GenomeKey	ID & AST Machine learning & Whole Genome	Bloodstream infections	LIV				

Formerly funded projects

Projects listed in this section were formerly funded, and are no longer supported by CARB-X for a variety of reasons

			Novelty/Type*			Therapeutics and Vaccines Development Stage			
CARB-X Final Investment Date	Therapeutics and Preventatives	Bacteria	New Abx Cls	New Abx Tgt	Non trad	Hit-to-Lead	Lead Optimization	Pre-Clinical	Phase I
Jenner Institute 03/25	NOMV Vaccine	*N. gonorrhoeae*	Vaccine						
Helmholtz HIPS 03/25	DnaN inhibitors for CABP infections	CABP bacteria	•						
GlyProVac 01/25	GPV02 glycosylated protein vaccine	*E. coli*	Vaccine						
Idorsia (formerly Vaxxilon) 11/24	VXN-319 vaccine	*K. pneumoniae*	Vaccine						
Microbiotix 8/24	T3SS Inhibitor: virulence modifier	*Pseudomonas aeruginosa*	•	•	•				
Vaxcyte (formerly SutroVax) 5/24	GAS Carbohydrate conjugate vaccine	Group A Streptococcus	Vaccine						
Phico Therapeutics 12/23	SASPject PT3.9: Engineered Bacteriophage	*Pseudomonas aeruginosa*	•	•	•				
Helmholtz Institute HIPS 8/23	HZI-HIPS Elastase (LasB) Inhibitors	*Pseudomonas aeruginosa*	•	•	•				
Summit Therapeutics 4/23	SMT-738 first-in-class LolCDE targeting antibiotic	CRE bacteria	•	•					
Basilea Pharmaceutica International 2/23	DXR Novel Class Inhibitor	Gram-negative pathogens	•	•					
Entasis Therapeutics 12/22	Non-beta-lactam PBPi	Gram-negative pathogens	•						
Evotec SE 12/22	TriBE broad spectrum antibiotics	Gram-negative, Gram-positive	•	•					
Eligo Bioscience 12/22	EB004. CRISPR-based bacteriophage	Gram-negative pathogens	Bacteriophage						
University of Queensland 11/22	OCTAPEPTIN Engineered peptides	Gram-negative pathogens	•		•				
BioVersys 09/22	BV300 Novel Class Pyrrolocytosines	ESKAPE, MRSA	•						
VenatoRx 09/22	Oral cyclic-boronate PBP inhibitor	*Neisseria gonorrhoeae*	•						
Microbiotix 09/22	Trans-translation inhibitors, oral antibiotic	MDR *Neisseria gonorrhoeae*	•	•					
Affinivax 09/22	MAPS vaccine	*S. aureus*	Vaccine						

Forge Therapeutics 09/22	FG-LpxC-LUNG. LpxC inhibitor	Gram-negative pathogens	•	•					
Debiopharm 07/22	Debio1454. FabI inhibitor	*Acinetobacter baumannii*	•						
ContraFect 04/22	Gram-negative lysins	*Pseudomonas aeruginosa*	•	•	•				
Spexis (formerly Polyphor) 03/22	OMPTA POL7306	Gram-negative ESKAPE pathogens	•	•					
Taxis Pharmaceuticals 03/22	EPI-PA Efflux Pump Inhibitor	*Pseudomonas aeruginosa*			•				
Lytica Therapeutics 03/22	StAMPS Large molecule direct-acting	Gram-negative pathogens	•						
BioVersys 01/22	AVATAR-SA Anti-virulence agent	*S. aureus*, MRSA			•				
Microbion 01/22	Novel bismuthiol, Pravibismane suspension	*P. aeruginosa, S. aureus,* NTM	•	•					
Oxford Drug Design 01/22	DaaRSi. Aminoacyl-tRNA Syn. Inhibitor	Gram-negative pathogens	•	•					
MicuRx 01/22	MRX-8. Soft drug polymyxin	Gram-negative pathogens							
Facile Therapeutics 04/21	EBSELEN Prevention of *C.difficile* recurrence	*C. difficile*	Small molecule						
Antabio 08/21	PEI Pseudomonas elastase inhibitor	*Pseudomonas aeruginosa*			•				
ContraFect 06/21	Amurins. Phage-encoded lytic	Gram-negative pathogens	•						
Idorsia 04/21	TopESKAPE. Topoisomerase inhibitor	*Acinetobacter, P. aeruginosa, Enterobacteriaceae*	•						
Techulon 04/21	PPNA-XPA	*P. aeruginosa* and *A. baumannii*			•				
Summit 09/20	SMT-571. Oral	*Neisseria gonorrhoeae*	•	•					
Zikani 08/20	Novel macrolide antibiotic	Gram-negative pathogens							
Forge Therapeutics 07/20	FG-LpxC-UTI. LpxC inhibitor	Gram-negative pathogens	•	•					
Bravos BB100 08/20	BB100 Monoclonal antibody	*Escherichia coli*			•				
Inhibrx 03/20	INBRX-111	*P. aeruginosa*			•				
Procarta 02/20	Pro-202 Oligonucleotidebased antibiotic	Gram-negative pathogens	•						
VenatoRx 12/19	VNRX-PBP. β-lact. resistant PBP inhibitor	*Enterobacteriaceae*	•						
SciBac 05/19	SCB-102	*C.difficile*	Microbiome						
Recida Tx 04/19	RC-01	*Enterobacteriaceae, P. aeruginosa*	•	•					
Curza 04/19	CZ-02	Broad spectrum	•						
Achaogen 03/19	Next-Generation AG	Gram-negative pathogens including *Pseudomonas*							
Melinta 02/19	Pyrrolocytosine	Broad spectrum	•						
Eligochem 12/18	Helical AMP	Gram-negative pathogens	•						
Shionogi 09/18	AGN-BL	*Enterobacteriaceae*							
Visterra 09/18	VIS705	*P. aeruginosa*			•				
Cidara Tx 04/18	CD201	*Acinetobacter, P. aeruginosa, Enterobacteriaceae*			•				
Achaogen 10/17	AKAO-LpxC	*P. aeruginosa*	•	•					
Redx Pharma 10/17	NBTI	*Acinetobacter, P. aeruginosa, Enterobacteriaceae*	•						

				Diagnostics Development Stage			
Company & CARB-X Final Investment Date	**Diagnostics**	**Syndrome**	**Healthcare Level**	**Feasibility**	**Optimization**	**Development**	**Verification & Validation**
SpeeDx 02/25	Resistance Plus InSignia Rapid Molecular ID/AST	Sexually transmitted infections	LIV				
Baebies 08/23	FINDER Bacteremia ID/AST	Neonatal Sepsis	LIII				
Accelerate Diagnostics 12/22	SRS Optical Imaging	Bloodstream infections	LIV				
Module Innovations 05/22	ID & AST ASTSENSe UTIs	Urinary Tract Infections	LIII				
Novel Microdevices 05/22	NOVEL DX Rapid Molecular Diagnostic	Sexually transmitted infections	LII				
Talis 08/21	POC Dx, Pathogen ID	Sexually transmitted infections	LII				
MicrobeDx 08/18	Near care Dx	Urinary Tract Infections	LII				

The above projects are supported by CARB-X utilizing non-dilutive funding from BARDA, Wellcome Trust, Germany's Federal Ministry of Education and Research (BMBF), with funding for specific projects from the UK Government's Global Antimicrobial Resistance
* New Antibiotic Class; New Molecular Target; Non-Traditional Product. Solid red arrows reflect completion of the stage, transparent coloring indicates current stage of development for active projects, and stage in which 'formerly funded' projects exited the portfolio. Arrow between stages indicate successful transition of the project through an Option stage gate.